Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19

Summary

The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 600 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in subjects from vulnerable communities that had direct contact with patients diagnosed with the disease.

Timeline

Start

2020-06

Primary completion

2020-08

Completion

2020-08

Drugs

Indications